الرئيسية
الأبحاث العلمية
التدريس
التدرج الوظيفى
السيرة الذاتية
البحث الأكاديمى
إتصل بنا
الموقع الجديد
المجالات البحثية
rug Formulation, Cancer Therapy, Gene Therapy, PEGylation, Liposomal delivery systems
الابحاث العلمية
1 -
A Novel Platform for Cancer Vaccines: Antigen-Selective Delivery to Splenic Marginal Zone B Cells via Repeated Injections of PEGylated Liposomes (2018).
2 -
A Cell Assay for Detecting Anti-PEG Immune Response against PEG-Modified Therapeutics (2018).
3 -
Design, in vitro/in vivo evaluation of meclizine HCl-loaded floating microspheres targeting pregnancy-related nausea and vomiting (2018).
4 -
Liposome co-incubation with cancer cells secreted exosomes (extracellular vesicles) with different proteins expressions and different uptake pathways (2018).
5 -
Doxorubicin Expands in Vivo Secretion of Circulating Exosome in Mice (2018).
6 -
Immune Response to PEGylated Nanomedicines: Impact of IgM Response (2018).
7 -
A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes (2018).
8 -
PEGylation and anti-PEG antibodies (2018).
9 -
A Novel Strategy to Increase the Yield of Exosomes (Extracellular Vesicles) for an Expansion of Basic Research (2018).
10 -
Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X‑ray Fluorescence Spectrometry (2018).
11 -
Reactivity of IgM antibodies elicited by PEGylated liposomes or PEGylated lipoplexes against auto and foreign antigens (2018).
12 -
Fast disintegrating tablet of Valsartan for the treatment of pediatric hypertension: In vitro and in vivo evaluation (2018).
13 -
Preparation and characterization of intravaginal vardenafil suppositories targeting a complementary treatment to boost in vitro fertilization process (2018).
14 -
Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model (2017).
15 -
Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity (2017).
16 -
Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules (2017).
17 -
Metronomic chemotherapy and nanocarrier platforms (2017).
18 -
Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model (2017).
19 -
Liposomal Delivery Systems: Design Optimization and Current Applications (2017).
20 -
Improvement of intratumor microdistribution of PEG ylated liposome via tumor priming by metronomic S-1 dosing (2016).
21 -
Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy (2016).
22 -
Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model (2016).
23 -
Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model (2016).
24 -
Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed (2015).
25 -
Intra-tumor distribution of PEGylated liposome upon repeated injection: No possession by prior dose (2015).
26 -
Relationship between the Concentration of Anti-polyethylene Glycol (PEG) Immunoglobulin M (IgM) and the Intensity of the Accelerated Blood Clearance (ABC) Phenomenon against PEGylated Liposomes in Mice (2015).
27 -
B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice (2014).
28 -
Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs (2014).
29 -
Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome (2014).
30 -
Activation of TLR9 by incorporated pDNA within PEG-coated lipoplex enhances anti-PEG IgM production (2014).
31 -
Application of Polyglycerol Coating to Plasmid DNA Lipoplex for the Evasion of the Accelerated Blood Clearance Phenomenon in Nucleic Acid Delivery (2014).
32 -
Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin (2014).
33 -
Liposomal Nanomedicine (2014).
34 -
The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage (2013).
35 -
Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration (2013).
36 -
Ex-vivo/in-vitro anti-polyethylene glycol (PEG) immunoglobulin M production from murine splenic B cells stimulated by PEGylated liposome (2013).
37 -
The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex (2013).
38 -
Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application (2013).
39 -
Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery (2013).
40 -
Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application (2012).
41 -
Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin (2012).
42 -
Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism? (2012).
43 -
Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model (2012).
44 -
A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA (2011).
45 -
Cationic liposomes and tumor vasculature targeting: A therapeutic approach that has potential for solid tumors (2011).
46 -
Targeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes (2010).
47 -
Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor (2010).
48 -
Recent advances in tumor vasculature targeting using liposomal drug delivery systems (2009).
49 -
Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model (2009).
50 -
Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model (2009).
51 -
Pharmaceutical Studies of Interactions Between Certain AntiHypertensive Drugs and Plasma Components or Their Substitutes. (1900).
تسجيل الدخول
دخول
2014 all rights reserved.
Zagazig University
جامعة المنصورة
جامعة الاسكندرية
جامعة القاهرة
جامعة سوهاج
جامعة الفيوم
جامعة بنها
جامعة دمياط
جامعة بورسعيد
جامعة حلوان
جامعة السويس
جامعة المنيا
جامعة دمنهور
جامعة المنوفية
جامعة أسوان
جامعة جنوب الوادى
جامعة قناة السويس
جامعة عين شمس
جامعة أسيوط
شراقوة | الشرقية بين ايديك
اخبار الشرقية - شراقوة | الشرقية بين ايديك
جامعة كفر الشيخ
جامعة السادات
جامعة طنطا
جامعة بنى سويف